Sandra Tong s a clinical development innovator with over 20 years’ pharma experience across all phases of drug development and multiple therapeutic areas. Most recently she was Vice President of Clinical Sciences and Drug Safety at Rigel Pharmaceuticals, where she was integral in worldwide approvals of Tavalisse™ for a rare autoimmune disease. Prior to this, she was Vice President of Clinical Development at Plexxikon Inc. and led multiple early phase oncology trials for innovative targeted, oral small molecules, one leading to approval of Turalio™ for a rare soft tissue tumor. Dr. Tong has led clinical programs at Affymax (Omontys™), Johnson and Johnson, Scios Inc., and Roche, with a focus on aligning the science between potential treatments and unmet medical needs.
Sandra received her Bachelor of Science degree at MIT and Doctor of Medicine degree at Johns Hopkins School of Medicine. She was on the faculty at UC-San Francisco as a physician-scientist rheumatologist before entering the pharmaceutical industry.